{
  "version": "1.0",
  "last_updated": "2025-01-17",
  "canonical_entity": "Strata by Venture Science",
  "description": "Public summary qualified in full by the definitive offering documents (PPM, LPA, Subscription Agreement). Accredited investors only; verification required prior to subscription.",
  "routes": {
    "html": "/facts",
    "json": "/facts.json",
    "txt": "/facts.txt",
    "faq": "/faq",
    "disclosures": "/disclosures"
  },
  "hero": {
    "title": "Strata by Venture Science",
    "subtitle": "AI & quantum thematic allocation for accredited investors",
    "badges": [
      "Accredited Only",
      "Quarterly NAV"
    ],
    "cta_primary": {
      "label": "Request Allocation",
      "url": "https://strata.venture-science.com/allocations"
    },
    "cta_secondary": {
      "label": "Schedule an intro meeting",
      "url": "https://calendly.com/oguz/30min"
    },
    "disclosure_short": "Accredited investors only; verification required prior to subscription."
  },
  "rag_summary": {
    "one_liner": "Strata by Venture Science is a thematic investment program (Delaware LP) focused on AI and quantum computing, offered under Regulation D to verified accredited investors, with quarterly liquidity windows.",
    "key_facts": [
      {
        "key": "Entity",
        "value": "Venture Science Strata Fund LP"
      },
      {
        "key": "Strategy",
        "value": "Thematic allocation: AI infrastructure, AI applications, quantum computing"
      },
      {
        "key": "Regulation",
        "value": "Regulation D — accredited investors only, verification required"
      },
      {
        "key": "Liquidity",
        "value": "Quarterly redemption windows; 60-day notice; 90-day payment"
      },
      {
        "key": "NAV cadence",
        "value": "Quarterly"
      },
      {
        "key": "Fees",
        "value": "1.5% management; 20% incentive (8% hurdle, catch-up)"
      },
      {
        "key": "Contact",
        "value": "ir@venture-science.com"
      }
    ]
  },
  "sections": [
    {
      "id": "fund_snapshot",
      "title": "Fund Snapshot",
      "content": [
        {
          "type": "bullets",
          "items": [
            "Legal entity: Venture Science Strata Fund LP",
            "Inception: 2025 (initial close pending)",
            "Structure: Closed-end private fund; capital commitments drawn via capital calls"
          ]
        }
      ]
    },
    {
      "id": "investment_objective",
      "title": "Investment Objective",
      "content": [
        {
          "type": "paragraph",
          "text": "Long-term capital appreciation through concentrated exposure to companies at the intersection of artificial intelligence and quantum computing."
        }
      ]
    },
    {
      "id": "investment_program",
      "title": "Investment Program / Thematic Focus",
      "content": [
        {
          "type": "bullets",
          "items": [
            "AI infrastructure (chips, cloud, data centers)",
            "AI applications (enterprise software, autonomous systems, genertic AI)",
            "Quantum computing hardware and software",
            "Hybrid AI–quantum ventures"
          ]
        },
        {
          "type": "paragraph",
          "text": "Geographic focus: primarily U.S.; opportunistic international. Asset classes: public equities, pre-IPO / late-stage private, SPVs, and secondary interests."
        }
      ]
    },
    {
      "id": "eligibility",
      "title": "Eligibility & Suitability",
      "content": [
        {
          "type": "bullets",
          "items": [
            "Regulation: Regulation D — general solicitation permitted; accredited-investor verification mandatory prior to subscription.",
            "Suitable for investors who: (a) meet accredited-investor standards, (b) can bear illiquidity and total loss, (c) seek thematic exposure to AI/quantum.",
            "Not suitable for investors requiring full liquidity, guaranteed returns, or short-term horizons."
          ]
        }
      ]
    },
    {
      "id": "subscription",
      "title": "Subscription Process",
      "subsections": [
        {
          "title": "Minimums",
          "content": [
            {
              "type": "bullets",
              "items": [
                "Additional subscriptions: $50,000",
                "GP may waive minimums at its sole discretion."
              ]
            }
          ]
        },
        {
          "title": "Steps",
          "content": [
            {
              "type": "bullets",
              "items": [
                "Complete accredited-investor verification (third-party or self-certification as permitted).",
                "Review PPM, LPA, and Subscription Agreement.",
                "Execute Subscription Agreement; submit KYC/AML documentation.",
                "Fund capital upon acceptance and capital call."
              ]
            }
          ]
        },
        {
          "title": "Timing",
          "content": [
            {
              "type": "bullets",
              "items": [
                "Subscriptions accepted on a rolling basis subject to GP discretion.",
                "Closings may occur monthly or quarterly; consult IR for current schedule."
              ]
            }
          ]
        }
      ]
    },
    {
      "id": "fees",
      "title": "Fees & Expenses",
      "subsections": [
        {
          "title": "Management Fee",
          "content": [
            {
              "type": "paragraph",
              "text": "1.5% per annum on committed capital (or net assets, per LPA), payable quarterly in advance."
            }
          ]
        },
        {
          "title": "Incentive Allocation",
          "content": [
            {
              "type": "bullets",
              "items": [
                "20% of net profits above an 8% preferred return.",
                "Catch-up provision applies; high-water mark in effect."
              ]
            }
          ]
        },
        {
          "title": "Fund Expenses",
          "content": [
            {
              "type": "paragraph",
              "text": "Organizational, legal, audit, custody, admin, and transaction costs borne by the Fund. See PPM for full schedule."
            }
          ]
        }
      ]
    },
    {
      "id": "liquidity",
      "title": "Liquidity & Withdrawals",
      "subsections": [
        {
          "title": "Redemption Windows",
          "content": [
            {
              "type": "paragraph",
              "text": "Quarterly (calendar quarter-end)."
            }
          ]
        },
        {
          "title": "Notice Period",
          "content": [
            {
              "type": "paragraph",
              "text": "60 days prior to quarter-end."
            }
          ]
        },
        {
          "title": "Payment",
          "content": [
            {
              "type": "paragraph",
              "text": "Generally within 90 days of quarter-end; GP may extend for illiquid positions."
            }
          ]
        },
        {
          "title": "Gate Provisions",
          "content": [
            {
              "type": "paragraph",
              "text": "GP may limit aggregate quarterly redemptions to 20% of NAV."
            }
          ]
        },
        {
          "title": "Lock-Up",
          "content": [
            {
              "type": "paragraph",
              "text": "12-month soft lock from subscription date; early redemption may incur a 2% fee."
            }
          ]
        }
      ],
      "note": "Interests are illiquid; there is no secondary market."
    },
    {
      "id": "valuation_nav",
      "title": "Valuation & NAV",
      "content": [
        {
          "type": "bullets",
          "items": [
            "NAV calculated quarterly by the Administrator.",
            "Public securities: closing prices; private holdings: fair-value estimates per GP valuation policy.",
            "Quarterly investor statements within ~45 days of quarter-end.",
            "Annual audited financials within ~120 days of fiscal year-end."
          ]
        }
      ]
    },
    {
      "id": "key_risks",
      "title": "Key Risks (Selected)",
      "risk_level": "HIGH",
      "content": [
        {
          "type": "bullets",
          "items": [
            "Total loss of capital is possible.",
            "Illiquidity — no guaranteed exit; secondary market does not exist.",
            "Concentration risk — thematic focus on AI/quantum may underperform.",
            "Valuation uncertainty — private holdings valued by GP; may differ from realization.",
            "Regulatory / technology risk — evolving laws and rapid obsolescence.",
            "Leverage — Fund may use leverage, amplifying gains and losses."
          ]
        },
        {
          "type": "paragraph",
          "text": "This is not a complete list. See PPM \"Risk Factors\" for comprehensive disclosure."
        }
      ]
    },
    {
      "id": "documents",
      "title": "Documents Available Upon Request",
      "content": [
        {
          "type": "bullets",
          "items": [
            "Private Placement Memorandum (PPM)",
            "Limited Partnership Agreement (LPA)",
            "Subscription Agreement",
            "Form ADV Part 2A (if applicable)"
          ]
        }
      ]
    },
    {
      "id": "contact",
      "title": "Contact",
      "content": [
        {
          "type": "bullets",
          "items": [
            "Investor Relations: ir@venture-science.com",
            "Website: venture-science.com"
          ]
        }
      ]
    },
    {
      "id": "legal_note",
      "title": "Legal / Offering Note",
      "content": [
        {
          "type": "paragraph",
          "text": "This summary is for informational purposes only and is qualified in its entirety by the Private Placement Memorandum, Limited Partnership Agreement, and Subscription Agreement. It does not constitute an offer to sell or a solicitation of an offer to buy any securities. Interests are offered only to verified accredited investors pursuant to Regulation D. Past performance is not indicative of future results."
        }
      ]
    }
  ]
}